NASDAQ:VNDA Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis $4.74 -0.25 (-5.01%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.77 +0.03 (+0.63%) As of 07/11/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Vanda Pharmaceuticals Stock (NASDAQ:VNDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vanda Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.74▼$5.0050-Day Range$3.92▼$5.0252-Week Range$3.81▼$6.37Volume557,075 shsAverage Volume599,650 shsMarket Capitalization$279.33 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingStrong Buy Company Overview Vanda Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders. The company’s research efforts are concentrated on conditions related to sleep and neurological diseases, with several late-stage and approved products addressing unmet medical needs. Vanda’s portfolio and pipeline reflect its commitment to innovative drug development in areas where treatment options are limited and patient populations are underserved. Among Vanda’s marketed products is Hetlioz (tasimelteon), a melatonin receptor agonist approved for the treatment of non-24-hour sleep-wake disorder in totally blind individuals. The company has also developed Fanapt (iloperidone), an atypical antipsychotic for schizophrenia, and Trudhesa (dihydroergotamine mesylate nasal spray) to address acute migraine attacks in adults. Vanda continues to advance its pipeline with investigational candidates targeting hepatic encephalopathy, dopamine-regulated disorders and other therapeutic areas within the CNS space. Founded in 2003 and headquartered in Washington, D.C., Vanda Pharmaceuticals operates a global research and development infrastructure, with facilities in North America and Europe. The company leverages strategic partnerships and collaborations to enhance its clinical programs and streamline regulatory pathways. Vanda’s team engages in ongoing dialogue with regulatory agencies to support its late-stage trials and potential label expansions for existing products. Under the leadership of President and Chief Executive Officer Mihael H. Polymeropoulos, Vanda maintains a scientific-driven approach, supported by an executive team with deep experience in neuroscience and drug commercialization. The company’s strategic priorities include advancing late-stage assets through pivotal studies, exploring new indications, and expanding its commercial footprint to better serve patients with CNS disorders worldwide.AI Generated. May Contain Errors. Read More Vanda Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreVNDA MarketRank™: Vanda Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 66th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingVanda Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVanda Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Vanda Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($1.12) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vanda Pharmaceuticals is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vanda Pharmaceuticals is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVanda Pharmaceuticals has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vanda Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.68% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently decreased by 96.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVanda Pharmaceuticals does not currently pay a dividend.Dividend GrowthVanda Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.77 Percentage of Shares Shorted7.68% of the float of Vanda Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVanda Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vanda Pharmaceuticals has recently decreased by 96.41%, indicating that investor sentiment is improving significantly. News and Social Media1.5 / 5News Sentiment0.63 News SentimentVanda Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vanda Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Vanda Pharmaceuticals insiders have bought 299.63% more of their company's stock than they have sold. Specifically, they have bought $128,400.00 in company stock and sold $32,130.00 in company stock.Percentage Held by InsidersOnly 8.90% of the stock of Vanda Pharmaceuticals is held by insiders.Percentage Held by Institutions88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vanda Pharmaceuticals' insider trading history. Receive VNDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VNDA Stock News HeadlinesInsider Selling: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Sells 7,000 Shares of StockJune 18, 2025 | insidertrades.comVNDA - Vanda Pharmaceuticals Inc Executives - MorningstarJuly 9, 2025 | morningstar.comMElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)VNDA - Vanda Pharmaceuticals Inc Chart - MorningstarJune 24, 2025 | morningstar.comMInsider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharmaceuticals Inc (VNDA)June 16, 2025 | gurufocus.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2SJune 10, 2025 | prnewswire.comVanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual MeetingMay 27, 2025 | prnewswire.comSee More Headlines VNDA Stock Analysis - Frequently Asked Questions How have VNDA shares performed this year? Vanda Pharmaceuticals' stock was trading at $4.79 on January 1st, 2025. Since then, VNDA shares have decreased by 1.0% and is now trading at $4.74. How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its quarterly earnings results on Wednesday, May, 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. The biopharmaceutical company had revenue of $50.04 million for the quarter, compared to analyst estimates of $45.13 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 8.30% and a negative net margin of 21.98%. Read the conference call transcript. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), GE Aerospace (GE), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2025Today7/13/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:VNDA CIK1347178 Webwww.vandapharma.com Phone(202) 734-3400Fax202-296-1450Employees290Year Founded2002Price Target and Rating Average Price Target for Vanda Pharmaceuticals$16.50 High Price Target$20.00 Low Price Target$13.00 Potential Upside/Downside+248.1%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.90 million Net Margins-21.98% Pretax Margin-27.63% Return on Equity-8.30% Return on Assets-6.85% Debt Debt-to-Equity RatioN/A Current Ratio3.93 Quick Ratio3.91 Sales & Book Value Annual Sales$198.77 million Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value$9.24 per share Price / Book0.51Miscellaneous Outstanding Shares58,930,000Free Float53,689,000Market Cap$279.33 million OptionableOptionable Beta0.68 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:VNDA) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.